Lenacapavir, a new HIV PrEP injection approved for EU use, shows 99.9% efficacy in global trials, offering the longest protection yet for at-risk groups.
WHO has identified 17 pathogens as top priorities for vaccine R&D to tackle major health threats, highlighting HIV, malaria, and tuberculosis, aiming to save millions of lives globally.
